

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
21 October 2021 (21.10.2021)



(10) International Publication Number
WO 2021/212026 A3

(51) International Patent Classification:
C07K 14/605 (2006.01) *A61K 9/00* (2006.01)
A61K 38/26 (2006.01)

TON, Massachusetts 02210 (US). **SRIVASTAVA, Ved P.**;
c/o Intarcia Therapeutics, Inc., One Marina Park Drive,
Suite 1300, Boston, Massachusetts 02210 (US).

(21) International Application Number:
PCT/US2021/027763

(74) Agent: **TRINQUE, Brian C.**; 28 State Street, Suite 700,
Boston, Massachusetts 02109 (US).

(22) International Filing Date:
16 April 2021 (16.04.2021)

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/011,641 17 April 2020 (17.04.2020) US

(71) Applicant: **INTARCIA THERAPEUTICS, INC.**
[US/US]; One Marina Park Drive, Suite 1300, Boston,
Massachusetts 02210 (US).

(72) Inventors: **BLACKWELL, William**; c/o Intarcia Thera-
peutics, Inc., One Marina Park Drive, Suite 1300, BOS-

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,

(54) Title: LONG ACTING GLUCAGON RECEPTOR SELECTIVE PEPTIDES AND METHODS OF USE




Fig. 1

(57) Abstract: This invention relates to isolated polypeptides that are long acting analogs of human glucagon. The disclosed glucagon analog polypeptides have beneficial physicochemical properties relative to endogenous human glucagon and known synthetic glucagon analog polypeptides, such as longer (*i.e.*, "long-acting") elimination half-lives ($t_{1/2}$), and improved solubility and thermal stability. This invention also relates to methods of using presently disclosed glucagon analog polypeptides in a variety of therapeutic indications, as well as methods of producing the same. The disclosed glucagon analog polypeptides are particularly useful in methods of treating metabolic diseases or disorders, such as type 2 diabetes, treating obesity, and providing weight loss, and in methods of treating non-alcoholic fatty liver disease (NAFLD) and/or nonalcoholic steatohepatitis (NASH).

[Continued on next page]

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

25 November 2021 (25.11.2021)